Physician profile
Richard S Legro
NPI 1235193863
$41,515.24
in general payments reported to CMS, 2019-2025
13 companies · $6,260 in 2025
The $6,260 reported for 2025 was more than what 95% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,661 · 2021: $3,000 · 2022: $7,687 · 2023: $4,685 · 2024: $12K · 2025: $6,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $2,502 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $641 · Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,393.76 |
| Travel and Lodging | $2,501.84 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $641.00 |
| Food and Beverage | $630.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Sa De Cv | $9,239.32 | 2024 | |
| Amag Pharmaceuticals, INC. | $7,562.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,410.71 | 2019 | |
| Eli Lilly and Company | $5,618.75 | 2025 | |
| Organon LLC | $4,685.00 | 2023 | |
| Novo Nordisk As | $3,000.00 | 2021 | |
| Exeltis, USA INC. | $2,765.00 | 2024 | Slynd |
| Abbvie INC. | $1,250.00 | 2019 | |
| Dexcom, INC. | $641.00 | 2025 | |
| Gynesonics, INC. | $145.67 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $124.95 | 2022 | |
| Ferring Pharmaceuticals INC. | $72.34 | 2024 | Menopur |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Legro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.